US/UK/Canada

Share

Contacts

  • Hansa Biopharma AB
    Scheelevägen 22 22363 Lund, Sweden
    +46 (0) 461 656 70
    http://www.hansabiopharma.com
    • Pick a time period -
    Tags ( Active)

    Hansa Biopharma to host conference call to provide interim results for January-March 2023 and a Business Update

    Lund, Sweden, April 14, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-March 2023 at 8:00 CET on April 20, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English. Slides used in the presentation will be live on the company website during the call under “Events &

    Hansa Medical Interim report July – September 2018

    July – September 2018 in brief ›› Hansa successfully completed two Phase 2 clinical studies evaluating imlifidase for kidney transplantation in highly sensitized patients, with imlifidase enabling transplantation in all 35 patients. ›› Imlifidase met all primary and secondary endpoints in each study. ›› Treatment with imlifidase enabled highly sensitized patients to receive life-saving transplants. ›› Hansa plans to submit Biologics License Application (BLA) and Marketing Authorization Application (MAA) filings by Q1 2019, with their potential acceptance of submission within 60

    Hansa Medical Interim report July – September 2017

    July-September in brief ›› Combined data from three independent clinical Phase II studies with Hansa Medical’s lead candidate IdeS was published in The New England Journal of Medicine 2017;377:442-53, August 3, 2017 issue. Data from these studies show that IdeS effectively reduces HLA antibodies and enables patients with very poor prognosis, who are unlikely to find a kidney donor, to be transplanted. Importantly, patients were doing well with good kidney function at last follow up. ›› Patient enrollment on target to have all patients recruited and treated by the end of 2017 in two

    Hansa Medical Interim report April-June 2017

    April – June 2017 in brief›› Continued patient enrolment in two ongoing Phase II studies with lead candidate IdeS in highly sensitized patients in the US and Europe. The objective is to have all 40 patients recruited and treated in the two separate studies by the end of 2017. All treated patients will be monitored for six months post treatment. ›› First patient treated in Phase II study with IdeS for acute renal failure in anti-GBM antibody disease. Approximately 15 patients will be recruited in this investigator initiated study at up to 15 clinics in Europe. The primary objective of

    Interim report January – March 2017

    January-March 2017 in brief›› Positive top-line results from the US clinical study with Hansa Medical’s lead candidate IdeS demonstrated that treatment with IdeS completely eliminates donor specific antibodies (DSAs), enabling transplantation of all 15 reported HLA incompatible patients. The clinical results will be presented at the American Transplant Congress (ATC) in Chicago, Illinois, on 30 April, 2017. ›› A Phase II study with IdeS in the rare autoimmune kidney disease anti-GBM antibody disease (anti-GBM) has been initiated. The study is investigator initiated at several European

    Hansa Medical Interim report July – September 2016

    Multicenter study initiated with IdeS in transplantation and expansion of clinical program into autoimmunity Third quarter in brief Business highlights›› Preliminary results presented from the Swedish ongoing Phase II study with IdeS in sensitized patients›› Hansa Medical initiated Highdes, a multicenter study in the US with IdeS for treatment of highly sensitized kidney transplantation patients›› Hansa Medical investigates cancer immunotherapy applications with IdeS and EndoS through the acquisition of UK based biotech company Immago Biosystems Ltd Significant events after

    Hansa Medical interim report January – March 2016

    Hansa Medical highlights January – March 2016›› Article in the New England Journal of Medicine supporting the need for and benefit of desensitization›› Strengthened shareholder base with several longterm institutional investors After the period›› FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation›› Ulf Wiinberg proposed as new chairman and Angelica Loskog as new board member›› Patient recruitment completed in Swedish Phase II clinical study with IdeS in kidney transplantation Financial summary first quarter 2016›› Net revenue for the group in

    Hansa Medical interim report January – September 2015

    January – September 2015 in summary Significant events during the third quarter · Hansa Medical received FDA Orphan Drug Designation for IdeS in solid organ transplant patients · First patient treated and transplanted with IdeS in US Phase II study at Cedars-Sinai Medical Center, Los Angeles · Positive IdeS Phase I data published in scientific journal PLOS ONE · Data from Hansa Medical’s first Phase II study of IdeS in Sensitized Kidney Transplantation Patients presented at an oral session at ESOT 2015 · Results from a clinical multicenter trial with HBP-assay published

    Hansa Medical Interim report January – June 2015

    January – June 2015 in summary  Operations Summary  Q1 Phase II clinical study of IdeS in highly sensitized patients awaiting kidney transplantation successfully completedCooperation initiated with leading US transplantation expert Dr Stanley Jordan at Cedars-Sinai Medical Center, Los AngelesDevelopment of a new generation of IdeS molecules for repeat dosing initiatedPreliminary application for listing on Nasdaq Stockholm submitted  Q2 IdeS Phase II study initiated at Uppsala University Hospital and Karolinska University Hospital. The first patient treated with IdeS was

    Hansa Medical Interim report January – March 2015

    Important initiatives for future growthJanuary – March 2015 in brief · Net sales in the group amounted to KSEK 3,847, compared to KSEK 1,612 for the same period 2014 · Consolidated net result was KSEK -10,725 (-5,998) · Operating result was KSEK -10,689 (5,896) · Earnings per share before and after dilution was SEK -0.41 (-0.26) · Phase II clinical study of IdeS successfully completed in highly sensitized dialysis patients awaiting kidney transplantation · Göran Arvidson appointed CFO and thereafter acting CEO · Cooperation initiated with leading US transplantation

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media